Roemmers LAC

active

 The proposed IFC investment comprises three loans totaling up to US$315 million equivalent (“the Project”) to three subsidiaries (the “Borrowers”) of Cormoran de Bilbao S.L. (“Roemmers” or the “Group”). The Project will be committed over a period of two years in the form of three senior secured corporate loans, including: (i) a US$45 million loan to be disbursed in USD to Laboratorios Siegfried S.A.S. (“Siegfried Colombia”) and Laboratorios Siegfried S.A. (“Siegfried Panama”) to partially finance the acquisition of Activa, S.A de C.V., Activa Energy, S.A. de C.V., and Activa Guatemala, S.A. de C.V. (together “Pharmedic”), a pharmaceutical manufacturing company based in El Salvador with operations in Guatemala, El Salvador, Honduras and Nicaragua (“Phase 1”),(ii) a US$20 million to be disbursed in Colombian Pesos (c. COP 78.0 billion) to Siegfried Colombia, of which US$5 million (c. COP 19.5 billion) will be own account and US$15 million (c. COP 58.5 billion) mobilized to support its capacity expansion in Colombia through the construction of a new manufacturing facility (“Phase 2”), and (iii) a US$250 million loan to be disbursed in Mexican Pesos (c. MXN 4.2 billion) to Siegfried Rhein, S.A. de C.V. (“Siegfried Mexico”), of which US$100 million (c. MXN 1.7 billion) will be own account and US$150 million (c. MXN 2.5 billion) mobilized, to support the construction of a new manufacturing facility in Mexico and potential acquisitions in Mexico (“Phase 3”).Siegfried Colombia, a fully owned subsidiary of Roemmers, is a leading pharmaceutical company focused on the development, manufacture and commercialization of over-the-counter medicines, prescription drugs and personal care products (mostly branded generics). With two manufacturing plants in Colombia and 840 employees, Siegfried Colombia is focused mainly on cardio, neuro, women’s health, and primary care therapeutic areas. Approximately 95% of Siegfried Colombia’s revenues are generated in Colombia, and the rest is exported to Central America, Ecuador, and Peru.Founded 45 years ago, Siegfried Mexico is a Mexico-based, pharmaceutical company fully owned by Roemmers focused on the development, manufacture, and commercialization of branded generic medicines. Siegfried Mexico (and its affiliates in Mexico) owns two manufacturing facilities located in Queretaro, Mexico. It is one of the leading domestic pharmaceutical companies in Mexico, primarily focused on prescription generics, with a portfolio of over 100 brands covering the following therapeutic areas: analgesics, antibiotics, cardiovascular, gastrointestinal, women’s health, central nervous system, and pediatrics. The Company has one of the largest pharmaceutical sales forces in Mexico and employs more than 1,600 people.